Trading Signals: FOLD Stock Price Prediction and Forecast (Thu. May. 31, 2007 - Fri. Dec. 22, 2023)(Amicus Therapeutics Inc)
| FOLD latest price $21.8750 (-6.4%) ($21.8750 - $21.8750) on Mon. Jan. 18, 2021. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 3.11% (three month average) | RSI | 37 | Latest Price | $21.8750(-6.4%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | FOLD declines -1.1% a day on average for past five trading days. | Weekly Trend | FOLD declines -1.1% a week on average for past two weeks. | Market Behavior | Normal for large cap. Normal for small cap. | Correlated ETFs | Broad market will support FOLD advance at 0% a week (0% probability) (0%) (0%) (0%) (0%) (0%) | Factors Impacting FOLD price | FOLD will decline at least -1.555% in a week (0% probabilities). (0%) (0%) (0%) (0%) (0%) | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -1.555% (StdDev 3.11%) | Hourly BBV | 0 () | Intraday Trend | 0% | | | |
|
1 - 5 Day Possible Target | $15.89(-27.36%) | Resistance Level | $23.23 | 5 Day Moving Average | $22.72(-3.72%) | 10 Day Moving Average | $22.79(-4.01%) | 20 Day Moving Average | $23.23(-5.83%) | To recent high | -12.2% | To recent low | 29.9% | Market Cap | $N/A | | | | Amicus Therapeutics, Inc. is a biotechnology company focused on discovering, developing, and delivering medicines for people living with rare metabolic diseases. The company is committed to advancing and expanding a pipeline of medicines for rare metabolic diseases, including a rare disease gene therapy portfolio. Amicus Therapeutics has a portfolio of product opportunities including the first and only approved oral precision medicine for people living with Fabry disease who have amenable genetic variants; a novel, clinical-stage, treatment paradigm for Pompe disease; and a rare disease gene therapy portfolio. The company was founded on February 4, 2002 and is headquartered in Cranbury, NJ. |